The latest vaccine to go to phase 3 testing may still emerge among the first to reach public use
newsdepo.com
On Tuesday, consumer pharmaceutical giant Johnson & Johnson announced that their vaccine for COVID-19 was entering phase 3 trials. It seems hard to get excited about yet another vaccine at this point, especially when others began their phase 3 trials weekThe latest vaccine to go to phase 3 testing may still emerge among the first to reach public use
On Tuesday, consumer pharmaceutical giant Johnson & Johnson announced that their vaccine for COVID-19 was entering phase 3 trials. It seems hard to get excited about yet another vaccine at this point, especially when others began their phase 3 trials weeks, or even months, ago. The focus on vaccines, including at Daily Kos, has been primarily on the “fast three”—Moderna, Pfizer/BioNTech, and Astrazeneca/Oxford—all of which involve innovative technology, and all of which are likely just weeks away from leaking out some results from the first wave of phase 3 volunteers. Just about every article, and every politician, discussing the idea of getting a vaccine by year’s end or in early 2021 has concentrated on one of these three. But there are reasons to think that when it finally comes time for most Americans to visit their local clinic for a COVID-19 vaccine, the answer may be: None of the above. Because there is a second wave of vaccines on the way that have genuine advantages, even if they don’t boast world-changing technology. In the case of the Johnson and Johnson vaccine, while it may seem like their vaccine is late to the ball, they could actually exit phase 3 ahead of their speedier competitors because their vaccine has a secret weapon: Unlike others, it’s just a single shot. Read more